Gene Therapy Market Size
The gene therapy market reached US$ 5.91 billion in 2025 and is expected to reach US$ 67.53 billion by 2035, growing at a CAGR of 23.1% during the forecast period 2026-2035.
Gene Therapy Market Overview
The gene therapy market is experiencing rapid growth, driven by advancements in genomics, biotechnology and personalized medicine. Gene therapy is revolutionizing genetic disorders, rare diseases and cancer treatments. The market has witnessed significant expansion due to the increasing R&D investments, strategic partnerships among key players and approval of novel gene therapies in emerging markets.
Gene Therapy Market Key Takeaways
- The market is expected to exceed US$ 67 billion by 2035, supported by increasing approvals for rare disease therapies and oncology applications.
- Viral vectors continue to dominate delivery technologies, accounting for 65.13% market share, reflecting their proven clinical efficiency.
- Rare diseases remain the primary commercial opportunity because many conditions still lack effective long-term treatment options.
- Premium pricing continues to challenge adoption, encouraging value-based reimbursement models and innovative payment structures.
- Gene editing platforms, including CRISPR technologies, are broadening future commercial opportunities beyond traditional gene replacement therapies.
- Large pharmaceutical companies continue expanding manufacturing capacity and strategic partnerships to strengthen commercial pipelines.
- Asia-Pacific is emerging as an attractive investment destination due to improving regulatory frameworks, biotechnology funding, and expanding clinical research infrastructure.
Market Scope
| Metrics | Details |
| Market Size (2025) | US$ 5.91 Billion |
| Market Size (2035) | US$ 67.53 Billion |
| CAGR (2026-2035) | 23.10% |
| Historic Years | 2023-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Segments Covered | Approach, Vector Type, Technique, Application, Region |
| Leading Region | North America |
| Fastest Growing Region | Asia-Pacific |
For more details on this report – Request for Sample
Gene Therapy Market Dynamics: Drivers & Restraints
Expansion into the rare diseases is significantly driving the gene therapy market growth
Rare diseases, which are genetic in nature, often have limited or no effective treatment options, making them ideal targets for gene therapies. The unique nature of these diseases presents a substantial opportunity for gene therapy to provide curative treatments where traditional approaches fail. For instance, Luxturna, a gene therapy treating children and adult patients with an inherited form of vision loss that may result in blindness. Luxturna is the first directly administered gene therapy approved in the U.S. that targets a disease caused by mutations in a specific gene.
Spinal Muscular Atrophy (SMA) is a rare genetic disorder that leads to progressive muscle weakness. Zolgensma, a gene therapy, offers a one-time treatment that has demonstrated significant improvements in survival and motor function for children with SMA. Hemophilia, another rare genetic disorder, requires lifelong treatment with clotting factor concentrates.
For instance, in February 2025, CSL Behring announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of HEMGENIX (etranacogene dezaparvovec-drlb) gene therapy for adults living with hemophilia B. As more gene therapies for rare diseases gain approval, the market will see a diversification of therapies, addressing a wider range of conditions.
High cost associated with the gene therapies are hampering the market growth
The high cost of gene therapies is one of the most significant challenges impacting the growth and accessibility of the gene therapy market. While gene therapies have shown curative potential for many serious diseases, their expensive price tags pose barriers to widespread adoption. For instance, the gene therapies Zynteglo and Skysona are priced at US$ 2.8 million and US$ 3 million per dose. Moreover, Zolgensma has a reported list price of US$ 2.1 million.
The development of gene therapies is an expensive, lengthy process. Clinical trials for gene therapies often span several years and involve high patient monitoring and expensive regulatory approval procedures. For instance, Luxturna, a gene therapy for Leber’s congenital amaurosis, took over 10 years from development to approval, and its cost is $850,000 per patient.
Many gene therapies are personalized treatments that are tailored to the genetic makeup of individual patients, requiring bespoke production for each case. This individualization further increases costs. For instance, CAR-T therapies such as Yescarta and Kymriah are customized for each patient by collecting and modifying the patient’s own T-cells, a process that involves complex manufacturing and quality control measures. These therapies can cost over $300,000 to $400,000 per patient.
Gene Therapy Market Segmentation Analysis
Segmented by Approach (Ex Vivo, In Vivo), by Vector Type (Viral Vectors, Non-Viral Vectors), by Technique (Gene Addition, Gene Silencing, Gene Editing), by Application (Oncology, Musculoskeletal Conditions, Blood Disorders, Rare Diseases, Ophthalmology, Others), and by Region, Share, Trends, and Forecast to 2035.
By Approach
Both ex vivo and in vivo approaches continue expanding across commercial and clinical applications. Ex vivo therapies dominate personalized oncology treatments, while in vivo approaches offer broader opportunities for treating inherited diseases through direct gene delivery.
By Vector Type
Viral vectors accounted for approximately 65.13% of the market due to their high delivery efficiency and well-established clinical performance.
Adeno-associated viruses, lentiviruses, adenoviruses, and gamma-retroviral vectors remain the preferred delivery systems across multiple therapeutic applications, while non-viral technologies continue gaining attention for improved safety and manufacturing flexibility.
By Technique
Gene addition currently represents the most mature commercial segment. However, gene editing technologies are attracting increasing investment because of their ability to permanently correct disease-causing mutations. Gene silencing approaches also continue expanding across neurological and metabolic disorders.
By Application
Rare diseases remain the largest revenue contributor because of strong regulatory incentives and limited therapeutic alternatives. Oncology represents another rapidly growing application area, supported by continued innovation in engineered immune cell therapies and personalized medicine.
Gene Therapy Market Regional Analysis
North America
North America maintains market leadership due to strong biotechnology investment, advanced genomic research infrastructure, favorable reimbursement frameworks, and early regulatory approvals. The United States remains the largest commercial market, supported by major biotechnology companies, academic research institutions, and specialized treatment centers.
Europe
Europe continues expanding through collaborative research initiatives, orphan drug incentives, and increasing adoption of advanced therapy medicinal products. Countries including Germany, France, and the United Kingdom continue strengthening manufacturing capabilities and clinical research networks.
Asia-Pacific
Asia-Pacific is projected to record the fastest growth through 2035. China, Japan, South Korea, and Australia continue increasing investments in biotechnology research, gene editing technologies, and domestic manufacturing infrastructure. Improving healthcare expenditure and supportive regulatory reforms further strengthen regional growth prospects.
Competitive Landscape and Company Product Mapping
Competition is increasingly centered on pipeline strength, manufacturing capabilities, delivery technologies, and disease specialization.
| Company | Primary Strategic Focus |
| Alnylam Pharmaceuticals | RNA therapeutics and genetic disease treatments |
| Spark Therapeutics | Inherited retinal disorders and AAV platforms |
| Novartis | Rare disease and hematology gene therapies |
| bluebird bio | Beta-thalassemia and sickle cell disease |
| Ferring Pharmaceuticals | Cell and gene therapy expansion |
| Vertex Pharmaceuticals | Gene editing and rare disease pipeline |
| Sarepta Therapeutics | Neuromuscular disorders |
| CSL Behring | Hemophilia gene therapies |
| Amgen | Strategic gene therapy investments |
| Orchard Therapeutics | Ultra-rare inherited diseases |
| Krystal Biotech | Dermatology gene therapies |
Leading companies continue strengthening competitive positioning through pipeline diversification, manufacturing expansion, strategic collaborations, and investment in next-generation delivery technologies.
Recent Developments
- April 2026 – Novartis, Vertex Pharmaceuticals, and Sarepta Therapeutics expand late-stage gene therapy pipelines
Leading biotech firms are advancing Phase 2/3 gene therapies targeting rare genetic disorders, neuromuscular diseases, and hematological conditions, accelerating commercialization timelines. - March 2026 – bluebird bio and CSL Behring focus on hematology and rare disease gene therapies
Companies are prioritizing treatments for beta-thalassemia, sickle cell disease, and hemophilia, with ongoing clinical trials and commercialization efforts. - March 2026 – Spark Therapeutics and Krystal Biotech advance AAV-based gene therapies
Adeno-associated virus (AAV) vectors remain a leading platform, supporting treatments for ophthalmology, dermatology, and rare genetic diseases. - February 2026 – Amgen and Ferring Pharmaceuticals expand investments in gene therapy R&D
Large pharma companies are increasing funding and partnerships to strengthen internal gene therapy pipelines and manufacturing capabilities. - February 2026 – Growth in in vivo gene editing and CRISPR-based therapies
Gene editing technologies, including CRISPR, are advancing rapidly, enabling precise, one-time treatments for previously untreatable genetic disorders. - January 2026 – Orchard Therapeutics and Alnylam Pharmaceuticals expand rare disease treatment portfolios
Companies are focusing on ultra-rare genetic disorders, leveraging gene therapy and RNA-based approaches to address unmet medical needs.
Target Audience
- Pharmaceutical Companies
- Biotechnology Companies
- Gene Therapy Developers
- Contract Manufacturing Organizations
- Healthcare Providers
- Hospital Networks
- Investors and Venture Capital Firms
- Research Institutions
- Government Healthcare Agencies
- Regulatory Authorities
- Genomic Technology Companies
- Strategic Consulting Firms
The global gene therapy market report delivers a detailed analysis with 73 key tables, more than 64 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.
